Global API market revenues to reach $143 billion in 2016
According to a New Market Report Published by Persistence Market Research, the Global API market is estimated to reach $186 billion by 2020, with North America accounting for 35% revenue shares..
The global API market was valued at US$ 135 billion in 2015 and is expected to grow at a year over year rate of 6.4% to reach $ 143 billion in 2016. North America will remain the most lucrative market for APIs, representing a revenue share of 35% in 2016.
Increase in global incidences of lifestyle related diseases and development of high potency APIs will continue to positively influence the global API market in 2016. Demand for active pharmaceutical ingredients is also growing due to increase in the geriatric population globally. These factors are expected to support the growth of the market in 2016 and beyond.
On the basis of manufacturing process type, the global pharmaceutical ingredient market is segmented into API manufacturing type and contract API. The API manufacturing includes captive or in-house API. In terms of revenue, captive manufacturing type accounted for higher share of the market than in-house API in 2015. However, owing to concerns regarding its limitation on manufacturing niche APIs and high production cost, manufacturers are looking for alternatives, fuelling the growth of the in-house API segment.
On the basis of API types, the market is segmented into synthetic chemical APIs and biological APIs. While synthetic chemical API segment accounted for a higher revenue share of the market in 2015, biological API is expected register a witness a higher year-over-year growth in 2016. Furthermore, major pharmaceutical companies are preferring biological API segment.
On the basis of drug type, branded API segment accounted for higher revenue share than over-the-counter (OTC) drugs, and generic prescription drugs in 2015. However, owing to their low cost manufacturing process, generic prescription drug segment is expected to expand at a higher year-over-year growth in 2016.
On the basis of therapeutic areas, the global API market is segmented into disorders such as metabolic, cardiovascular, oncology, neurological, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and other therapeutic uses. Cardiovascular Drugs is the largest segment in terms of revenues, accounting for a revenue share of 24% in 2015. On the other hand, the oncology segment is expected to witness the highest year-over-year growth in 2016 over 2015.
Asia Pacific is the second-largest market for APIs globally, with factors, such as availability of low cost production facilities making the region a key manufacturing hub globally. The region is home to over 60% of world's population, with a high percentage that can be categorised as geriatric.
Key players in the global API market include Teva Pharmaceutical Industries Ltd., and Zhejiang NHU Co., Ltd, Zhejiang Medicine Co.North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Sandoz (Novartis AG), Zhejiang Huahai Pharmaceutical Co.,Ltd, Ltd and Zhejiang Hisun Pharmaceutical Co., Ltd.
Long-term Outlook: The global active pharmaceutical ingredients market is expected to increase at a CAGR of 6.6% during the forecast period from 2015 to 2020 and reach US$185 Bn in revenues by 2020 end. North America will remain the largest market, with revenues increasing at a CAGR of 6.6% during the forecast period.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance